Cara Therapeutics Inc (CARA):企業の財務・戦略的SWOT分析

◆英語タイトル:Cara Therapeutics Inc (CARA) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C15041
◆発行会社(調査会社):GlobalData
◆発行日:2019年3月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD300 ⇒換算¥44,400見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD600 ⇒換算¥88,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥133,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cara Therapeutics Inc (Cara Therapeutics) is a biotechnology company that develops and commercializes chemical entities for acutepain, chronic pain and pruritus. The company offers kappa opioid receptor agonists in the therapeutic areas of acute pain, chronic pain, neuropathic pain and pruritus. Its lead product candidate includes KORSUVA injection, which is in Phase III clinical trial for the treatment of patients with chronic kidney disease associated pruritus undergoing hemodialysis, and dialysis of patients suffering from uremic pruritus. Cara Therapeutics develops molecules at novel analgesic and anti-inflammatory targets using proprietary drug screening technology. The company serves pharmaceutical and healthcare sectors. Cara Therapeutics is headquartered in Stamford, Connecticut, the US.

Cara Therapeutics Inc Key Recent Developments

Nov 06,2018: Cara Therapeutics reports third quarter 2018 financial results
Oct 30,2018: Cara Therapeutics to Announce Third Quarter 2018 Financial Results on November 6, 2018
Oct 23,2018: Cara Therapeutics appoints Joana Goncalves, M.D., as Chief Medical Officer
Aug 07,2018: Cara Therapeutics Reports Second Quarter 2018 Financial Results
Aug 06,2018: Cara Therapeutics appoints christopher A. Posner to board of directors

This comprehensive SWOT profile of Cara Therapeutics Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Cara Therapeutics Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Cara Therapeutics Inc – Key Information
Cara Therapeutics Inc – Overview
Cara Therapeutics Inc – Key Employees
Cara Therapeutics Inc – Key Employee Biographies
Cara Therapeutics Inc – Key Operational Heads
Cara Therapeutics Inc – Major Products and Services
Cara Therapeutics Inc – History
Cara Therapeutics Inc – Company Statement
Cara Therapeutics Inc – Locations And Subsidiaries
Cara Therapeutics Inc – Key Manufacturing facilities
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Cara Therapeutics Inc – Business Description
Cara Therapeutics Inc – Corporate Strategy
Cara Therapeutics Inc – SWOT Analysis
SWOT Analysis – Overview
Cara Therapeutics Inc – Strengths
Cara Therapeutics Inc – Weaknesses
Cara Therapeutics Inc – Opportunities
Cara Therapeutics Inc – Threats
Cara Therapeutics Inc – Key Competitors

Section 3 – Company Financial Performance Charts

Cara Therapeutics Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Cara Therapeutics Inc, Key Information
Cara Therapeutics Inc, Key Ratios
Cara Therapeutics Inc, Share Data
Cara Therapeutics Inc, Major Products and Services
Cara Therapeutics Inc, History
Cara Therapeutics Inc, Key Employees
Cara Therapeutics Inc, Key Employee Biographies
Cara Therapeutics Inc, Key Operational Heads
Cara Therapeutics Inc, Other Locations
Cara Therapeutics Inc, Subsidiaries
Cara Therapeutics Inc, Key Manufacturing facilities
Cara Therapeutics Inc, Key Competitors
Cara Therapeutics Inc, SWOT Analysis
Cara Therapeutics Inc, Ratios based on current share price
Cara Therapeutics Inc, Annual Ratios
Cara Therapeutics Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

Cara Therapeutics Inc, Performance Chart
Cara Therapeutics Inc, Ratio Charts

★海外企業調査レポート[Cara Therapeutics Inc (CARA):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Synergy:企業の戦略・SWOT・財務分析
    Synergy - Strategy, SWOT and Corporate Finance Report Summary Synergy - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Hargreaves Lansdown PLC:企業の戦略・SWOT・財務情報
    Hargreaves Lansdown PLC - Strategy, SWOT and Corporate Finance Report Summary Hargreaves Lansdown PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Absher Construction Company:企業の戦略・SWOT・財務分析
    Absher Construction Company - Strategy, SWOT and Corporate Finance Report Summary Absher Construction Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • TriLink BioTechnologies Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary TriLink BioTechnologies Inc (TriLink), a subsidiary of Maravai Life Sciences Inc, is a manufacturer of modified nucleic acid products. The company’s products include oligonucleotides, nucleotides, custom chemistry, DNA synthesis reagents, cleanamp PCR products, modified nucleoside triphospha …
  • The Singing Machine Company, Inc.:戦略・SWOT・企業財務分析
    The Singing Machine Company, Inc. - Strategy, SWOT and Corporate Finance Report Summary The Singing Machine Company, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Rolta India Ltd (ROLTA):企業の財務・戦略的SWOT分析
    Rolta India Ltd (ROLTA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Public Broadcasting Service:企業の戦略・SWOT・財務情報
    Public Broadcasting Service - Strategy, SWOT and Corporate Finance Report Summary Public Broadcasting Service - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Universiteit Utrecht-製薬・医療分野:企業M&A・提携分析
    Summary Universiteit Utrecht (Universiteit Utrecht) is a research university that offers education programs. The university offers bachelors, master's, honor education, education for professionals, online education, training and other education courses. Its research areas include earth and sustainab …
  • Vergnet SA (ALVER):企業の財務・戦略的SWOT分析
    Vergnet SA (ALVER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Globin Solutions Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Globin Solutions Inc (Globin) is a pre-clinical stage biotechnology company with focus on the research and development of antidotal medicines for human poisoning. Its lead compound, Ngb H64Q, an antidote, a mutant version of the protein neuroglobin, has been found to scavenge carbon monoxide …
  • Bellerophon Therapeutics Inc (BLPH):製薬・医療:M&Aディール及び事業提携情報
    Summary Bellerophon Therapeutics Inc (Bellerophon Therapeutics), formerly Bellerophon Therapeutics LLC is a clinical-stage biotherapeutics company that focuses on the development of therapies for the treatment of cardiopulmonary diseases. The company’s lead investigational cardiopulmonary product ca …
  • Anavex Life Sciences Corp (AVXL):企業の財務・戦略的SWOT分析
    Anavex Life Sciences Corp (AVXL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Harbin Electric International Co Ltd:企業の戦略的SWOT分析
    Harbin Electric International Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Odebrecht S.A.:企業の戦略・SWOT・財務情報
    Odebrecht S.A. - Strategy, SWOT and Corporate Finance Report Summary Odebrecht S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Editas Medicine Inc (EDIT):製薬・医療:M&Aディール及び事業提携情報
    Summary Editas Medicine Inc (Editas Medicine) formerly Gengine Inc, is a discovery stage biotechnology company that develops genome level treatments for rare diseases. The company is developing a proprietary genome editing platform based on its in-licensed clustered regularly interspaced short palin …
  • Seoul National University Hospital:企業の戦略的SWOT分析
    Seoul National University Hospital - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Intech Biopharm Ltd (6461):医療機器:M&Aディール及び事業提携情報
    Summary Intech Biopharm Ltd (Intech Biopharm) is a drug developing company that develops drugs for obstructive airway diseases. The company provides marketed products such as single ingredient generics such as Synvent, and Duasma, developed for asthma; and multi-ingredient generic, Synflutide, for a …
  • ICU Medical Inc (ICUI)-医療機器分野:企業M&A・提携分析
    Summary ICU Medical Inc (ICU Medical) is a medical device company which develops, manufactures, distributes and sells devices used for infusion therapy, cancer diagnosis and treatment and critical care applications. The company’s major products include needle free vascular access devices, closed sys …
  • Apotex Inc-製薬・医療分野:企業M&A・提携分析
    Summary Apotex Inc (Apotex) produces and markets a wide range of generic pharmaceuticals. It also undertakes the research, development, manufacture and distribution of non-prescription and private label medicines, fine chemicals and disposable plastics for medical use. The company has research and d …
  • Merit Medical Systems Inc (MMSI):企業の製品パイプライン分析2018
    Summary Merit Medical Systems, Inc. (Merit Medical) offers a wide range of single-use medical devices for interventional and diagnostic procedures. The company’s products include inflation devices and accessories, diagnostic and therapeutic catheters, diagnostic and hydrophilic products, thrombolyti …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆